Previous Close | 12.36 |
Open | 12.41 |
Bid | 12.99 x 300 |
Ask | 13.10 x 400 |
Day's Range | 12.41 - 13.20 |
52 Week Range | 5.27 - 27.97 |
Volume | |
Avg. Volume | 524,063 |
Market Cap | 805.904M |
Beta (5Y Monthly) | 0.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for TMCI
Treace 100K+ Lapiplasty® Patients Treace Medical Celebrates 100K+ Lapiplasty® Patients Lauren - Lapiplasty® Patient and Collegiate Diver Lauren, Lapiplasty® Patient and Collegiate Diver Lauren - Lapiplasty® Patient Lapiplasty® Patient Lauren Working Out Treace Lapiplasty® Procedure Lapiplasty® - The Future of Bunion Surgery is Here Treace Further Expands Focus on Bunion Deformity Education by Sponsoring First-Ever National Bunion Day in the U.S. on April 16, 2024 Launches New “Future You” Patien
PONTE VEDRA, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance. Recent Highlights Revenue of $62.2 million in fourth quarte
Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ETPONTE VEDRA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2023 after